Proteome Profiles of Hypercholesterolemic Patients with and Without FH Treated with a PCSK9 Inhibitor: A Comparison of Depleted and Nondepleted Samples in a Pilot Study
PROTEOMICS – Clinical Applications · 2026-05 · 20 (3)
DOI: 10.1002/prca.70043 ↗At a glance
Vergleichsstudie in PROTEOMICS – Clinical Applications, published online on 2026-03-29. Written by Dana Dlouha and 4 co-authors. Institution: Center For Experimental Medicine, Institute of Clinical and Experimental Medicine, Prague, Czech Republic. Major MEDLINE topics: PCSK9 Inhibitors, Hyperlipoproteinemia Type II, Proteome. Cited 1 times so far (Crossref); 66 references. Funded by: Ministry of Health of the Czech Republic, Czech Health Research Council, Ministerstvo Zdravotnictví Ceské Republiky.
Abstract (original language)
Background
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors offer a novel approach for reducing low‐density lipoprotein cholesterol (LDL‐C) levels in patients with familial hypercholesterolemia (FH). In our study, we aimed to compare the plasma proteome profiles of heterozygous FH (HeFH) patients and non‐FH patients treated with PCSK9 inhibitors (PCSK9i).
Methods
We analyzed 132 plasma samples from 38 patients. Samples were collected before the start of the PCSK9i treatment and then again at the third, sixth, and 12 th months of treatment. Using LC‒MS technology, we compared two approaches: depleted and nondepleted samples.
Results
Across all time points of treatment, numerous differentially expressed proteins were detected regardless of the FH status compared to baseline. We identified only three proteins with downregulated expression—PCSK9, CRTAC1, and PON1—with p adj
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Center For Experimental Medicine, Institute of Clinical and Experimental Medicine, Prague, Czech Republic.
- Institute of Biotechnology, Czech Academy of Sciences, Vestec, Czech Republic.
- Department of Clinical Biochemistry, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
- First Faculty of Medicine, Charles University, Prague, Czech Republic.
- Faculty of Medicine, Charles University, Hradec Králové, Czech Republic.
- 3rd Department of Internal Medicine - Metabolism and Gerontology, University Hospital Hradec Králové, Hradec Králové, Czech Republic.
ORCID profiles: Dana Dlouha
Funding
- Ministry of Health of the Czech Republic
- Czech Health Research Council
- Ministerstvo Zdravotnictví Ceské Republiky
- Agentura Pro Zdravotnický Výzkum České Republiky
Cite
APA
Dlouha, D., Pompach, P., Horackova, J., Hubacek, J. A., & Blaha, V. (2026). Proteome Profiles of Hypercholesterolemic Patients with and Without FH Treated with a PCSK9 Inhibitor: A Comparison of Depleted and Nondepleted Samples in a Pilot Study. PROTEOMICS – Clinical Applications, 20(3). https://doi.org/10.1002/prca.70043
Vancouver
Dlouha D, Pompach P, Horackova J, Hubacek JA, Blaha V. Proteome Profiles of Hypercholesterolemic Patients with and Without FH Treated with a PCSK9 Inhibitor: A Comparison of Depleted and Nondepleted Samples in a Pilot Study. PROTEOMICS – Clinical Applications. 2026;20(3). doi:10.1002/prca.70043
BibTeX
@article{Dlouha2026,
author = {Dlouha, Dana and Pompach, Petr and Horackova, Jana and Hubacek, Jaroslav Alois and Blaha, Vladimir},
title = {Proteome Profiles of Hypercholesterolemic Patients with and Without FH Treated with a PCSK9 Inhibitor: A Comparison of Depleted and Nondepleted Samples in a Pilot Study},
journal = {PROTEOMICS – Clinical Applications},
year = {2026},
volume = {20},
number = {3},
doi = {10.1002/prca.70043}
}
EUVIMED